Sam Brusco, Associate Editor08.14.23
Promex, a company focused on assembly of small devices containing semiconductor chips for the medical, biotech, and communications markets, have named David Fromm as its new chief operating officer (COO). The promotion and new title adds to Fromm’s current role as VP of engineering at Promex.
Fromm will oversee Promex’s full breadth of operations, including technical developments for assembly and manufacturing of complex medical devices that use microelectronics. He will lead operations, engineering, and business development teams from the company’s Santa Clara, Calif. facility.
He joined Promex in 2023 after working with the company as a customer for almost a decade.
“Dave has walked in the shoes of OEM engineers, project leads, and procurement decision-makers. He is uniquely qualified to bring a customer-focused perspective to every aspect of the Promex business,” Richard Otte, Promex CEO told the press. “He understands how to partner for turnkey, vertically integrated approaches to creating the smallest, most complex medical devices that are enabled with microelectronics.”
Fromm most recently led R7D for hardware and tech for next-gen platforms at Cepheid, as director of instrument research. He partnered with Promex to develop and build critical subassemblies in a ruggedized, point-of-care molecular diagnostic device.
“I needed a partner capable of iterating and building out the vision, from a blank piece of paper through design maturity, for very complex projects,” said Fromm. “My leadership at Promex is shaped by what appealed to me as a customer—the company’s capabilities, flexibility, and problem-solving skills. Promex can take early, abstract requirements and scale them into successful production and commercialization.”
Fromm also has experience as a senior optical scientist at Theranos and research scientist at Agilent Technologies.
Fromm will oversee Promex’s full breadth of operations, including technical developments for assembly and manufacturing of complex medical devices that use microelectronics. He will lead operations, engineering, and business development teams from the company’s Santa Clara, Calif. facility.
He joined Promex in 2023 after working with the company as a customer for almost a decade.
“Dave has walked in the shoes of OEM engineers, project leads, and procurement decision-makers. He is uniquely qualified to bring a customer-focused perspective to every aspect of the Promex business,” Richard Otte, Promex CEO told the press. “He understands how to partner for turnkey, vertically integrated approaches to creating the smallest, most complex medical devices that are enabled with microelectronics.”
Fromm most recently led R7D for hardware and tech for next-gen platforms at Cepheid, as director of instrument research. He partnered with Promex to develop and build critical subassemblies in a ruggedized, point-of-care molecular diagnostic device.
“I needed a partner capable of iterating and building out the vision, from a blank piece of paper through design maturity, for very complex projects,” said Fromm. “My leadership at Promex is shaped by what appealed to me as a customer—the company’s capabilities, flexibility, and problem-solving skills. Promex can take early, abstract requirements and scale them into successful production and commercialization.”
Fromm also has experience as a senior optical scientist at Theranos and research scientist at Agilent Technologies.